Experienced in Allergic Conjunctivitis

Pietro Quaglino

Turin, IT 
Experienced in Allergic Conjunctivitis
Turin, IT 
OverviewLocationsClinical Research

Overview

Pietro Quaglino practices in Turin, Italy. Mr. Quaglino is rated as an Experienced expert by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Sezary Syndrome, Mycosis Fungoides, and T-Cell Lymphoma.

His clinical research consists of co-authoring 578 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Allergic Conjunctivitis.

Gender
Male

Locations

Turin, Italy
Other Locations
Piemonte, Italy
Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

578 Total Publications

Classic Lichen planopilaris and pseudopelade of Brocq of the scalp: a retrospective study of epidemiological, histopathological and etiopathogenetic differences.
Classic Lichen planopilaris and pseudopelade of Brocq of the scalp: a retrospective study of epidemiological, histopathological and etiopathogenetic differences.
Journal: Italian journal of dermatology and venereology
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Quaglino's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 28 Advanced Conditions
View All 90 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile